A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
Amgen has created a number of websites to better serve you with specific questions.
As an industry leader in the development of biologic medicines and biosimilars, Amgen advocates for policies in Europe based on sound science that will improve and protect the health of patients with serious illnesses, support advances in clinical development and enhance access to medicines.
Access to Medicines
At Amgen, we believe that breakthrough medicines are the best hope for patients in the fight against serious diseases. To realize the full value of our medicines and for the people who need them most, Amgen is delivering integrated access and health system solutions. Read more
Amgen works constructively with payers, health technology assessment (HTA) agencies and policymakers, in Europe and around the world, to find pragmatic solutions to shared challenges, ensuring patients get access to the medicines they need when they need them. Our team contributes to technical debates on the timely reimbursement of medicines and is engaging in discussions globally on valuing medicines and financing their reimbursement across different healthcare systems.
Healthcare as an Investment
As many societies continue to grapple with the economic and fiscal pressures of the pandemic, Amgen advocates for the need for sustained investment in health in order to improve societal health, advance equity and foster economic recovery.
Amgen believes it is critical to ensure Europe has the right environment to discover, develop, manufacture and deliver the next generation of treatments to patients.
Therapeutic Area Policy
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for policy solutions that improve patient health outcomes.
As a proven biologics leader with a portfolio of 11 biosimilars, Amgen is tireless in our efforts to develop and deliver high quality biosimilars that support a more resilient health system while ensuring that patients have access to much-needed treatment options. Competition created by reliably supplied, high-quality biosimilars has the potential to alleviate some of the financial burden for governments, hospitals, and patients, while delivering the clinical benefits of reference biologic medicines. Amgen believes policies that support both innovation in originator biological products and competition from biosimilars promote a robust and sustainable marketplace with biosimilars.
Environmental, Social & Governance (ESG)
Our ESG efforts are grounded in our mission to serve patients, from our endeavors to strengthen science education and inspire the next generation of scientists, to expanding access to our medicines and supporting efforts to strengthen healthcare systems to better serve patients in need worldwide while also pursuing a more environmentally sustainable business model. Read more
Amgen Europe was established
Employees in Europe
R&D Employees Globally
EU Countries with Amgen Sites